Article

Phase II study begins for Allegro VMT treatment

Allegro Ophthalmics LLC has announced the start of a phase II study of ALG-1001 in patients with vitreomacular traction (VMT).

San Juan Capistrano, CA-Allegro Ophthalmics LLC has announced the start of a phase II study of ALG-1001 in patients with vitreomacular traction (VMT).

The study is a placebo-controlled, randomly assigned, double-masked, dose-ranging trial to evaluate the safety and efficacy of intravitreal injections of the drug in patients with VMT.

Patients are currently being enrolled at multiple sites outside the United States, with the primary efficacy endpoint of release of VMT being determined by optical coherence tomography images read by Duke Reading Center.

Secondary endpoints include the observation of non-surgical closure of full thickness macular holes and forgone need for pars plana vitrectomy.

“Current options for treating VMT are limited for the majority of patients,” said David Boyer, MD, clinical professor of ophthalmology at the University of Southern California’s Keck School of Medicine and member of Allegro’s scientific advisory board. “While this is the first human study using (the drug) to treat VMT, the success of it in achieving total resolution of posterior vitreous detachment in earlier studies gives us great optimism for the current study in VMT.”

“We are excited about the initiation of this phase II clinical study with (the drug) for a third indication,” said Vicken Karageozian, MD, co-founder and chief technical officer, Allegro Ophthalmics. “Following study results from other indications-along with allowance from the FDA to proceed with phase II studies-we are confident that this study will continue to affirm the safety and efficacy of (the drug), and are hopeful that it will provide meaningful therapeutic benefits to patients with VMT.”

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.